Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases

Ateş, Öztürk; Yalçın, Şuayib

doi:10.4103/ijc.ijc_430_18

Cited by 3 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its denotation is derived from the virus inducing rapidly accelerated fibrosarcoma (v-RAF). Of the orthologs of this murine gene discovered in the human genome, one designated B-RAF, which is coding for serine-threonine kinase, is mutated in a significant portion of human cancers (29)(30)(31)(32)(33)(34)(35). According to these and other reports, RAF mutations are associated with 10 to 15% of human cancers, it is less than RAS mutations.…”

Section: Occurrence Of Carcinogenic Mutations In B-raf a Downstream S...mentioning

confidence: 94%

“…The most frequent oncogenic B-RAF mutation is located in codon 600 (in earlier reports mistaken for codon 599), leading to substitution of valine for glutamic acid (V600E). This mutation has been detected in up to 90% of B-RAF-mutated cancers (32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48). Data on the presence of V600E mutation in these cancers are shown in Table 4.…”

Section: Occurrence Of Carcinogenic Mutations In B-raf a Downstream S...mentioning

confidence: 99%

“…Data on the presence of V600E mutation in these cancers are shown in Table 4. V600E mutation has been detected in 10-15% of CRC (33)(34)(35)(36)(37)(38) but has been rare in LC (39,40) and PDC (41). However, approximately 40-60% of MEL (42)(43) harbour this mutation.…”

Section: Occurrence Of Carcinogenic Mutations In B-raf a Downstream S...mentioning

confidence: 99%

See 2 more Smart Citations

Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility?

Vonka¹,

Hirsch²

2021

Cent Eur J Public Health

View full text Add to dashboard Cite

The dramatic progress in tumour biology and immunology in the past several years has opened new avenues for the treatment and prevention of cancer. One of the great contributions of the immunotherapeutic approaches is an increasing understanding of the immunology of cancer, which is, gradually creating conditions for the development of prophylactic anti-cancer vaccines. Efficient vaccines have been developed and employed for the prophylaxis of two frequent cancers of viral origin, namely cervical cancer and liver cancer. The new knowledge on the interactions between the immune system and the malignant tumors seems to provide means for the development of prophylactic vaccines against cancers developing due to the mutations in the proto-oncogenes converting their products into oncoproteins. According to the present estimates, these cancers form a great majority of human malignancies. Recent evidence has indicated that the immune system recognizes such mutated proteins, and that the development of cancer is due to the failure of the immune system to eliminate neoplastic cells. Followingly, it can be expected that inducing immunity against the mutated epitopes will increase the capacity of the body to deal with the initiated precancerous cells. In the present paper this hypothesis is primarily discussed in the relationship with colorectal cancer (CRC), which seems to be a well-fitting candidate for prophylactic vaccination. CRC is the third most frequent malignancy and the fourth most common cause of cancer mortality. Mutations of two proto-oncogenes, namely RAS and RAF, are involved in the majority of CRC cases and, in addition, they are shared with other human malignancies. Therefore, the strategy to be used for prophylaxis of CRC is discussed together with several other frequent human cancers, namely lung cancer, pancreatic duct cancer and melanoma. The prophylactic vaccines proposed are aimed at the reduction of the incidence of these and, to a lesser extent, some other cancers.

show abstract

Section: Occurrence Of Carcinogenic Mutations In B-raf a Downstream S...mentioning

confidence: 94%

Section: Occurrence Of Carcinogenic Mutations In B-raf a Downstream S...mentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility?

Vonka¹,

Hirsch²

2021

Cent Eur J Public Health

View full text Add to dashboard Cite

show abstract

“…The responses were mixed, and no conclusion could be drawn regarding the best therapeutic approach. Survival data was available only for ten patients, averaging 21.6 months [4,5,6,[11][12][13][14][15][16][17][18][19].…”

Section: Management and Outcomementioning

confidence: 99%

“…[4][5][6][12][13][14][15][16][17][18][19].J Gastrointestin Liver Dis, June 2020 Vol. 29 No 2: 253-258…”

mentioning

confidence: 99%

The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review

Afrăsânie

Gafton

Marinca

et al. 2020

JGLD

View full text Add to dashboard Cite

Background and Aims: The coexistence of RAS and BRAF mutations is extremely rare, occurring in approximately 0.05% of patients with metastatic colorectal cancer (mCRC). Starting from a case presentation, this review aims to examine the prevalence, clinical, histopathological and molecular features of tumors with concomitant mutations. Methods: Case report and systematic review. We performed a systematic literature search in PubMed and EMBASE using the following MeSH terms: “coexistence” OR “concomitant” AND “RAS” AND “BRAF” AND “colorectal cancer” from the inception of the databases onwards. Results: We present the case of a 53-year-old man diagnosed with metastatic rectal adenocarcinoma with both a KRAS and a BRAF mutation. The review included eleven papers reporting on a total of 30 mCRC cases with concomitant RAS and BRAF mutations. The male/female ratio was 11/5. The average age was 58.5 years. The tumor was located in nine cases on the right colon and in two cases in the left colon. 43.3% of subjects had liver metastases, and 6.6% had lung metastases. Next-generation sequencing (NGS) was used in 36.6% of cases and polymerase chain reaction (PCR) in 16.6% of cases. KRAS mutations were present in 83.3% of patients and NRAS mutations in 16.6% of patients. Survival could be assessed in 10 patients and the median was 21.1 months (about 30% lower than the survival in the general mCRC population). Conclusion: The results of this systematic review suggest the need to design a cohort study (either prospective or retrospective) to better characterize the patients with concomitant RAS and BRAF mutations and to establish the optimal treatment for this rare situation.

show abstract

Pathological Complete Response to Second Line Chemotherapy in a Patient with Cervical Lymph Node Metastasis from Transverse Colon Cancer with RAS and BRAF V600E Mutations: A Case Report

悠記

圭

利貞

et al. 2021

Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi

View full text Add to dashboard Cite

Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases

Cited by 3 publications

References 19 publications

Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility?

Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility?

The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review

Pathological Complete Response to Second Line Chemotherapy in a Patient with Cervical Lymph Node Metastasis from Transverse Colon Cancer with RAS and BRAF V600E Mutations: A Case Report

Contact Info

Product

Resources

About